Abbott announced FDA authorization of its Libre Duo 10 Day system, the world’s first dual glucose-ketone sensing technology. The new biowearable is designed to alert people living with… read more.
A multicenter randomized clinical trial led by researchers from the Pain Outcomes Lab at Wake Forest University School of Medicine found that high-frequency spinal cord stimulation significantly reduced pain and… read more.
Eli Lilly and Company announced that the FDA approved Mounjaro (tirzepatide), a dual GIP and GLP-1 hormone receptor agonist, to lower the risk of major adverse cardiovascular (CV)… read more.
Various forms of physical exercise may help prevent diabetes during pregnancy (or gestational diabetes), but data are limited. In a randomized clinical trial published in Acta Obstetricia et Gynecologica… read more.
Personal care products are among the largest everyday sources of exposure to endocrine-disrupting chemicals, and high schoolers who follow social media influencers or watch beauty tutorials seem to… read more.
Ultragenyx Pharmaceutical announced that the FDA granted accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr), also known as DTX 401, in adult and pediatric patients eight years and older with… read more.
A new study published in Diabetes Care finds that bone loss alone does not explain the increased fracture risk observed in some older adults with type 2 diabetes. The article, “Type… read more.
A multi-institutional study led by researchers at Children’s Hospital of Philadelphia (CHOP) found that telemedicine is becoming increasingly common for problem-based primary care, particularly for children with endocrine… read more.
The type of menopause symptoms, as well as their severity, can differ greatly among women. A number of earlier studies have suggested various reasons for those differences. A… read more.
Abbott announced a first-of-its-kind partnership with Google Health to redefine how people understand and manage their health. By combining glucose insights from Abbott’s Lingo biowearable with Google’s expertise… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) authorised orforglipron (Foundayo), making the UK the first country in Europe to approve this GLP-1 tablet for weight management and type 2 diabetes. Alongside a reduced-calorie diet and increased… read more.
New research by UCLA Health found GLP-1 medications may reduce the risk of serious fractures for adults with type 2 diabetes. Adults with type 2 diabetes and obesity… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
